"A European court has upheld a ruling which found Lundbeck engaged in anti-competitive activity that delayed the launch of generic versions of its big-selling antidepressant Celexa.
The 2013 verdict by the European Commission resulted in a €94m ($106m) fine for the Danish drugmaker, which was held to have paid four generics firms to stay out of the market in order to keep the price of Celexa (citalopram) artificially high.
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around €52m, and those judgments have also been upheld by the General Court of the EU"
The 2013 verdict by the European Commission resulted in a €94m ($106m) fine for the Danish drugmaker, which was held to have paid four generics firms to stay out of the market in order to keep the price of Celexa (citalopram) artificially high.
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around €52m, and those judgments have also been upheld by the General Court of the EU"
Full European Commission documentation about the case
Comments
Post a Comment